tirzepatide vs rybelsus Semaglutide Trial Results Wegovy vs Rybelsus | Semaglutide

31 In a trial evaluating semaglutide for weight loss, the incidence of acute pancreatitis was still low (3 of 1,306 participants) despite a higher dose and more significant weight loss, but none of the 655 individuals in the placebo group developed pancreatitis

Common Side Effects and Safety Considerations Understanding potential side effects helps set realistic expectations

Tirzepatide has shown similar results: in a phase 2 trial, up to 73.3% of participants at the highest dose achieved MASH resolution without worsening fibrosis at 52 weeks, compared to 13.2% on placebo

Semaglutide is a clinically proven GLP-1 receptor agonist that works with your body's natural appetite and blood sugar regulation systems to make sustainable weight loss actually achievable